Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells.

Ochoa MC, Perez-Ruiz E, Minute L, Oñate C, Perez G, Rodriguez I, Zabaleta A, Alignani D, Fernandez-Sendin M, Lopez A, Muntasell A, Sanmamed MF, Paiva B, Lopez-Botet M, Berraondo P, Melero I.

Oncoimmunology. 2019 Apr 13;8(7):1599636. doi: 10.1080/2162402X.2019.1599636. eCollection 2019.

PMID:
31143521
2.

Analysis of monocitary subpopulations in relation to cardiovascular risk factors.

Marcos Jubilar M, Orbe J, Roncal C, Fernández Montero A, Colina I, Rodil R, Rodriguez JA, Zabaleta A, Paiva B, Pastrana JC, Páramo JA.

Clin Investig Arterioscler. 2019 Jul - Aug;31(4):152-159. doi: 10.1016/j.arteri.2019.02.003. Epub 2019 Apr 6. English, Spanish.

PMID:
30967277
3.

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.

Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, Blanco L, Lasa M, Maiso P, Rodriguez I, Garate S, Jelinek T, Segura V, Moreno C, Merino J, Rodriguez-Otero P, Panizo C, Prosper F, San-Miguel JF, Paiva B.

Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28.

PMID:
30692097
4.

Immunophenotypic Pattern of De Novo Malignancy After Liver Transplantation.

González JP, Zabaleta A, Sangro P, Basualdo JE, Burgos L, Paiva B, Herrero JI.

Transplant Proc. 2019 Jan - Feb;51(1):77-79. doi: 10.1016/j.transproceed.2018.04.090. Epub 2019 Jan 14.

PMID:
30655139
5.

Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy.

González-Morales A, Zabaleta A, García-Moure M, Alonso MM, Fernández-Irigoyen J, Santamaría E.

J Proteomics. 2019 Mar 1;194:168-178. doi: 10.1016/j.jprot.2018.11.020. Epub 2018 Nov 29.

PMID:
30503830
6.

Mycobacterioses identified in the National Reference Laboratory of Colombia from 2012 to 2016

Llerena C, Valbuena A, Zabaleta AP.

Biomedica. 2018 Aug 1;38(0):87-94. doi: 10.7705/biomedica.v38i0.4143.

7.

Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection.

González-Morales A, Zabaleta A, Guruceaga E, Alonso MM, García-Moure M, Fernández-Irigoyen J, Santamaría E.

Oncotarget. 2018 Jul 24;9(57):31045-31065. doi: 10.18632/oncotarget.25774. eCollection 2018 Jul 24.

8.

Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.

Bocanegra Gondan AI, Ruiz-de-Angulo A, Zabaleta A, Gómez Blanco N, Cobaleda-Siles BM, García-Granda MJ, Padro D, Llop J, Arnaiz B, Gato M, Escors D, Mareque-Rivas JC.

Biomaterials. 2018 Jul;170:95-115. doi: 10.1016/j.biomaterials.2018.04.003. Epub 2018 Apr 3.

PMID:
29656235
9.

[Estimation of underreporting of Chikungunya virus infection cases in Girardot, Colombia, from November, 2014, to May, 2015].

Pacheco Ó, Martínez M, Alarcón Á, Bonilla M, Caycedo A, Valbuena T, Zabaleta A.

Biomedica. 2017 Dec 1;37(4):507-515. doi: 10.7705/biomedica.v37i4.3370. Spanish.

10.

[Prevalence of Mycobacterium tuberculosis resistance to quinolones and injectables in Colombia, 2012-2013].

Llerena C, Zabaleta A, Valbuena A, Murcia M.

Biomedica. 2017 Jan 24;37(1):96-103. doi: 10.7705/biomedica.v37i2.3204. Spanish.

11.

[Characterization of clinical isolates of Mycobacterium tuberculosis from HIV positive individuals in Colombia, 2012].

Castro C, Ricardo A, Zabaleta A, Llerena C, Puerto G.

Biomedica. 2017 Jan 24;37(1):86-95. doi: 10.7705/biomedica.v37i1.3112. Spanish.

12.

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD.

Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.

13.

Microdosed Lipid-Coated (67)Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes.

Ruiz-de-Angulo A, Zabaleta A, Gómez-Vallejo V, Llop J, Mareque-Rivas JC.

ACS Nano. 2016 Jan 26;10(1):1602-18. doi: 10.1021/acsnano.5b07253. Epub 2016 Jan 5.

PMID:
26678549
14.

Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance.

Zabaleta A, Riezu-Boj JI, Larrea E, Villanueva L, Lasarte JJ, Guruceaga E, Fisicaro P, Ezzikouri S, Missale G, Ferrari C, Benjelloun S, Prieto J, Sarobe P.

J Med Virol. 2016 May;88(5):843-51. doi: 10.1002/jmv.24399. Epub 2015 Oct 19.

PMID:
26447929
15.

[Tuberculosis and drug-resistance tuberculosis in prisoners. Colombia, 2010-2012].

Gómez IT, Llerena CR, Zabaleta AP.

Rev Salud Publica (Bogota). 2015 Jan-Feb;17(1):97-105. Spanish.

16.

Drafting the proteome landscape of myeloid-derived suppressor cells.

Gato M, Blanco-Luquin I, Zudaire M, de Morentin XM, Perez-Valderrama E, Zabaleta A, Kochan G, Escors D, Fernandez-Irigoyen J, Santamaría E.

Proteomics. 2016 Jan;16(2):367-78. doi: 10.1002/pmic.201500229. Epub 2015 Dec 14. Review.

PMID:
26403437
17.

[Evaluation of the BD MGITTM technique for identifying the Mycobacterium tuberculosis complex].

Gómez IT, Llerena CR, Zabaleta AP.

Rev Salud Publica (Bogota). 2014 Sep-Oct;16(5):765-71. Spanish.

18.

Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection.

Zabaleta A, D'Avola D, Echeverria I, Llopiz D, Silva L, Villanueva L, Riezu-Boj JI, Larrea E, Pereboev A, Lasarte JJ, Rodriguez-Lago I, Iñarrairaegui M, Sangro B, Prieto J, Sarobe P.

Mol Ther Methods Clin Dev. 2015 Mar 11;2:15006. doi: 10.1038/mtm.2015.6. eCollection 2015.

19.

An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.

Hernández-Gil J, Cobaleda-Siles M, Zabaleta A, Salassa L, Calvo J, Mareque-Rivas JC.

Adv Healthc Mater. 2015 May;4(7):1034-42. doi: 10.1002/adhm.201500080. Epub 2015 Apr 2.

PMID:
25846677
20.

Simulation climate change impact on runoff and sediment yield in a small watershed in the basque country, northern Spain.

Zabaleta A, Meaurio M, Ruiz E, Antigüedad I.

J Environ Qual. 2014 Jan;43(1):235-45. doi: 10.2134/jeq2012.0209.

PMID:
25602556
21.

Toward defining the anatomo-proteomic puzzle of the human brain: An integrative analysis.

Fernandez-Irigoyen J, Labarga A, Zabaleta A, de Morentin XM, Perez-Valderrama E, Zelaya MV, Santamaria E.

Proteomics Clin Appl. 2015 Oct;9(9-10):796-807. doi: 10.1002/prca.201400127. Epub 2015 Feb 24. Review.

PMID:
25418211
22.

Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L.

Llopiz D, Huarte E, Ruiz M, Bezunartea J, Belsúe V, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P.

Oncoimmunology. 2013 Dec 1;2(12):e27009. Epub 2013 Dec 5.

23.

Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.

Echeverria I, Pereboev A, Silva L, Zabaleta A, Riezu-Boj JI, Bes M, Cubero M, Borras-Cuesta F, Lasarte JJ, Esteban JI, Prieto J, Sarobe P.

Hepatology. 2011 Jul;54(1):28-37. doi: 10.1002/hep.24325. Epub 2011 May 14.

24.

Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C).

Echeverría I, Zabaleta A, Silva L, Díaz-Valdés N, Riezu-Boj JI, Lasarte JJ, Borrás-Cuesta F, Civeira MP, Prieto J, Sarobe P.

J Viral Hepat. 2008 Nov;15(11):782-9. doi: 10.1111/j.1365-2893.2008.01020.x. Epub 2008 Jul 10.

PMID:
18637068
25.

Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.

Zabaleta A, Llopiz D, Arribillaga L, Silva L, Riezu-Boj JI, Lasarte JJ, Borrás-Cuesta F, Prieto J, Sarobe P.

Mol Ther. 2008 Jan;16(1):210-7. Epub 2007 Oct 9.

26.

Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.

Llopiz D, Dotor J, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P.

Cancer Immunol Immunother. 2008 Jan;57(1):19-29. Epub 2007 Jun 13.

27.

Structured group-based education for type 2 diabetes in primary care.

Zabaleta AM, Forbes A.

Br J Community Nurs. 2007 Apr;12(4):158-62. Review.

PMID:
17505331
28.

[Health related quality of life in patients with diabetes mellitus type 2].

Hervás A, Zabaleta A, De Miguel G, Beldarráin O, Díez J.

An Sist Sanit Navar. 2007 Jan-Apr;30(1):45-52. Spanish.

29.

Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.

Zabaleta A, Arribillaga L, Llopiz D, Dotor J, Lasarte JJ, Prieto J, Borrás-Cuesta F, Esteban JI, Quer J, Vayreda F, Sarobe P.

Antiviral Res. 2007 Apr;74(1):25-35. Epub 2007 Jan 22.

30.

Engineered promiscuous T helper peptides for the induction of immune responses.

Ruiz M, Llopiz D, Zabaleta A, Lasarte JJ, Borrás-Cuesta F, Sarobe P.

Mol Immunol. 2007 Mar;44(9):2205-12. Epub 2006 Dec 8.

31.

[Impact of common reasons for consultation on the feeling of vitality and the physical performance of the over-65s].

Sánchez Lasheras T, Goñi Ruiz N, Serrano-Martínez M, Buil P, Zabaleta A, de Miguel G, Beldarrain O, Díez Espino J.

Aten Primaria. 2005 Mar 31;35(5):246-52. Spanish.

32.

Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors.

Stefansson S, Yepes M, Gorlatova N, Day DE, Moore EG, Zabaleta A, McMahon GA, Lawrence DA.

J Biol Chem. 2004 Jul 16;279(29):29981-7. Epub 2004 May 6.

33.

Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.

Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, Borrás-Cuesta F, Prieto J.

J Virol. 2003 Oct;77(20):10862-71.

34.

Modification of ocular defects in mouse developmental glaucoma models by tyrosinase.

Libby RT, Smith RS, Savinova OV, Zabaleta A, Martin JE, Gonzalez FJ, John SW.

Science. 2003 Mar 7;299(5612):1578-81.

35.

Environmental transformation of the Bilbao estuary, N. Spain: microfaunal and geochemical proxies in the recent sedimentary record.

Cearreta A, Irabien MJ, Leorri E, Yusta I, Quintanilla A, Zabaleta A.

Mar Pollut Bull. 2002 Jun;44(6):487-503.

PMID:
12146832
36.

Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice.

Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL, John SW.

Nat Genet. 2002 Jan;30(1):81-5. Epub 2001 Dec 17.

PMID:
11743578
37.

Haploinsufficient Bmp4 ocular phenotypes include anterior segment dysgenesis with elevated intraocular pressure.

Chang B, Smith RS, Peters M, Savinova OV, Hawes NL, Zabaleta A, Nusinowitz S, Martin JE, Davisson ML, Cepko CL, Hogan BL, John SW.

BMC Genet. 2001;2:18. Epub 2001 Nov 6.

38.

The mouse anterior chamber angle and trabecular meshwork develop without cell death.

Smith RS, Zabaleta A, Savinova OV, John SW.

BMC Dev Biol. 2001;1:3. Epub 2001 Feb 14.

39.

Genetic modification of glaucoma associated phenotypes between AKXD-28/Ty and DBA/2J mice.

Anderson MG, Smith RS, Savinova OV, Hawes NL, Chang B, Zabaleta A, Wilpan R, Heckenlively JR, Davisson M, John SW.

BMC Genet. 2001;2:1. Epub 2001 Jan 15.

40.

Haploinsufficiency of the transcription factors FOXC1 and FOXC2 results in aberrant ocular development.

Smith RS, Zabaleta A, Kume T, Savinova OV, Kidson SH, Martin JE, Nishimura DY, Alward WL, Hogan BL, John SW.

Hum Mol Genet. 2000 Apr 12;9(7):1021-32.

PMID:
10767326
41.

Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice.

Chang B, Smith RS, Hawes NL, Anderson MG, Zabaleta A, Savinova O, Roderick TH, Heckenlively JR, Davisson MT, John SW.

Nat Genet. 1999 Apr;21(4):405-9.

PMID:
10192392
42.

[EXTRAPERITONEAL CESAREAN SECTION. SOME CONSIDERATIONS].

MILANES J, ZABALETA A.

Rev Colomb Obstet Ginecol. 1964 Jul-Aug;15:341-3. Spanish. No abstract available.

PMID:
14209579

Supplemental Content

Loading ...
Support Center